Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 368

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

Medical imaging and nuclear medicine: a Lancet Oncology Commission

Open access
Hricak, Hedvig, Abdel-Wahab, May, Atun, Rifat, Lette, Miriam Mikhail, Paez, Diana, Brink, James A, Donoso-Bach, Lluís, Frija, Guy, Hierath, Monika, Holmberg, Ola, Khong, Pek-Lan, Lewis, Jason S, McGinty, Geraldine, Oyen, Wim J G, Shulman, Lawrence N, Ward, Zachary J, Scott, Andrew M·2021·The Lancet Oncology

Abstract

Executive Summary The diagnosis and treatment of cancer patients requires access to imaging to ensure accurate management decisions and optimal outcomes. Our global assessment of imaging and nuclear medicine resources identified major shortages of equipment and workforce, particularly in low- and middle-income countries (LMIC). A microsimulation model of 11 cancers showed scale-up of imaging would avert 3.2% (2.46 million) of all cancer deaths caused by the modeled cancers between 2020-2030, saving 54.92 million life years. Scale-up of imaging, treatment and care quality would avert 9.55 million (12.5%) of all deaths caused by the modeled cancers, saving 232.30 million life years. Scale-up of imaging would cost $6.84 billion in 2020-2030 but yield global lifetime productivity gains of $1.23 trillion, a net return of $179.19 per $1 invested. Using a conservative human capital approach, scale-up of imaging would provide a net benefit of $209.46 billion and net return of $31.61 per $1 invested. Using the same model and a full income approach, combining scale-up of imaging and treatment and quality of care would provide a net benefit of $2.66 trillion, and a net return of $12.43 per $1 invested. These improved health and economic outcomes were seen across all countries and geographical regions. We propose actions and investment that would enhance access to imaging equipment, workforce capacity, digital technology, radiopharmaceuticals, and research and training programs in LMIC, to realise massive health and economic benefits and reduce the burden of cancer globally.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30751-8

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 117 references

Cited by

See all 368

Metadata

Authors
Hricak, H., Abdel-Wahab, M., Atun, R., Lette, M. M., Paez, D., Brink, J. A., Donoso-Bach, L., Frija, G., Hierath, M., Holmberg, O., Khong, P.-L., Lewis, J. S., McGinty, G., Oyen, W. J. G., Shulman, L. N., Ward, Z. J., & Scott, A. M.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-04
Volume
22
Issue
4
Pages
e136-e172
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3135115453
Cited by
368
References
117
FWCI
24.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medical imaging and nuclear medicine: a Lancet Oncology Commission. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30751-8
The paper
Hricak, H., Abdel-Wahab, M., Atun, R., Lette, M. M., Paez, D., Brink, J. A., Donoso-Bach, L., Frija, G., Hierath, M., Holmberg, O., Khong, P.-L., Lewis, J. S., McGinty, G., Oyen, W. J. G., Shulman, L. N., Ward, Z. J., & Scott, A. M. (2021). Medical imaging and nuclear medicine: a Lancet Oncology Commission. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30751-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.